Common questions leave important answers unknown
TB-500 answers start with what hasn't been proved
TB-500 is the fragment people discuss for healing. Here you'll find twenty-five answers about research, safety and access. Human benefits remain unproved. Your answers need to keep that missing proof in view.
The name doesn't establish a medicine
TB-500 isn't a proved medicine. Its name doesn't measure strength. You can read why researchers study repair.
TB-500 is made from one section of a protein
To make TB-500, labs use parts 17–23 of thymosin beta-4, whose forty-three parts form a chain. The fragment's lab weight is about 889 daltons, tiny units for weighing very small substances. The fragment is one substance, rather than a mixture. That smaller size doesn't show whether the substance helps you.
TB-500's name doesn't state TB-500 strength
The letters TB are short for thymosin beta. TB-500 is the lab-made thymosin beta-4 fragment's name among researchers and people treating animals. The complete protein has a different name. You can't infer dose, size or strength from the number in the name.
TB-500 repair research mainly concerns animals and dishes
Studies examine wounds, blood vessels, and injured hearts and brains using animals or cells growing in lab dishes [5]. Much work uses whole thymosin beta-4, which helps cells move during repair. That movement is a reason for research, not proof of a treatment. The fragment has no approved human use, so your benefit remains unproved.
TB-500 and BPC-157 share missing human safety proof
Thymosin beta-4 provides the fragment used to make TB-500. BPC-157 is made from part of a stomach protein. A 2026 Sports Medicine review reported helpful animal healing findings for both, but weak human safety proof [11]. Neither has approval, and animal healing doesn't settle your benefit.
Animal heart repair tests used the complete protein
Full-protein tests helped animal heart cells survive. Animal hearts also grew blood vessels. Those gains don't prove TB-500 helps your heart.
TB-500 shares a part used when cells change shape
Cells use actin to build strands for movement, and the fragment holds this protein [1]. Whole thymosin beta-4 also helped animal heart cells survive and vessels grow [2]. Those are different findings from simply helping movement. You can't assume the fragment gives every benefit seen with the larger protein.
TB-500 hasn't shown the same heart changes in people
With whole thymosin beta-4, animal heart cells survived better and cells on the heart surface became active [2][7]. TB-500 hasn't shown those same effects in people. No completed heart trial has compared the fragment with another treatment. Your heart benefit remains a question rather than a proved gain.
TB-500 heart claims need to account for failed animal tests
Rodent hearts had less damage after heart attacks with thymosin beta-4 [9]. In a pig test, stopping then restoring blood flow left treatment without a helpful result. The fragment hasn't proved protection in human treatment comparisons. Those mixed animal results can't promise protection for your heart.
Human thymosin beta-4 safety work differs from heart treatment proof
People received thymosin beta-4 through a vein in an early Phase 1 safety test [6]. Other human tests used eye drops. An early heart-attack trial using shots was canceled before anyone joined. Your heart benefit can't be established by planned tests or by the safety and eye-drop tests that took place.
TB-500 blood-vessel claims also raise questions about tumors
With thymosin beta-4, cells forming vessel linings move more and new vessels form [5]. Added blood supply could aid repair or support tumor growth. Several cancers have more of the protein, which is linked to vessel growth in tumors [11]. You have a possible safety concern without a measured human risk from the fragment.
Wounds improved in animals while other tests brought no gain
Animal wounds improved. Mouse muscle fibers grew without added strength. These answers explain why your benefit is still unproved.
TB-500 hasn't proved wound repair for your skin
With whole thymosin beta-4, rat wounds had 42% more new skin growth at 4 days and up to 61% more at 7 days [3]. Wounds shrank more, grew vessels and gained collagen, which gives strength to your skin. The fragment shares a part used during cell movement. You're still without proof that the fragment heals human wounds.
TB-500 muscle claims need more than new fibers
In animals, thymosin beta-4 drew cells that build muscle toward an injury [5]. Mice missing a needed muscle protein grew more fibers without gaining strength. The fragment hasn't proved faster recovery after your exercise. More cells don't always mean stronger muscle, as those mice showed.
TB-500 tendon healing in people remains unproved
Thymosin beta-4 helped rats heal the ligament on the knee's inner side [5]. Your ligament holds bones together, while your tendon fastens muscle to bone. Few tests directly studied these injuries, and the fragment hasn't proved human benefits. Most research concerns skin and wounds, leaving your tendon question unanswered.
TB-500 hair claims haven't been confirmed in human tests
Thymosin beta-4 made hair-growing cells active in mice and rats [5]. The animals grew hair faster. Researchers haven't shown that TB-500 makes hair grow in people. You can't predict a human hair change from those animal findings.
TB-500 brain protection remains an unanswered human question
Rats with strokes received thymosin beta-4 in shots inside the belly [4]. Brain function improved at 2 and 12 milligrams per kilogram, adjusted to the rat's weight. Rats had no gain with 18 milligrams per kilogram. Those rat results don't establish brain protection for you with the fragment.
TB-500 inflammation claims rely on tests of whole protein
Thymosin beta-4 reduced inflammation and cell deaths in animals and in cells studied in dishes [5]. A rodent liver test also found less scarring [14]. Another test changed the protein only in certain liver cells, showing that effects depended on the test [15]. Relief of your inflammation hasn't been established for the fragment.
Short tests can't answer years of safety questions
Your long-term safety remains unknown. Cancer concerns lack human answers. Rat healing times don't predict how soon your injury improves.
TB-500 cancer findings raise a concern without measuring your risk
Higher thymosin beta-4 levels occur in several cancers, where the protein is linked to spread and new vessels feeding tumors [11]. Repair-related actions could also aid cancer growth. Researchers haven't shown whether the smaller fragment causes human cancer. You don't have a measured risk, but the concern hasn't been ruled out.
TB-500 side effects need testing of the fragment itself
Human safety research on the fragment is limited. An early Phase 1 safety test gave people whole thymosin beta-4 through a vein, up to 1260 milligrams [6]. Reported problems ranged from mild to moderate, without harm stopping larger-amount tests. Cancer-growth concerns remain unanswered [11], so that short test can't settle the fragment's safety for you.
Years of TB-500 use haven't been shown safe
Human tests over years of TB-500 use are missing. Researchers haven't settled cancer concerns [11] or completed trials comparing human treatments. The short Phase 1 safety test used the complete protein [6]. You can't stretch that brief test into proof of safety over years.
TB-500 lacks completed trials comparing treatments in people
A completed trial comparing TB-500 with another treatment in people is missing. Healthy people received whole thymosin beta-4 through a vein in an early Phase 1 safety test, up to 1260 milligrams [6]. Harm didn't stop tests of larger amounts. Eye-drop trials used the larger protein for dry eyes, without establishing the fragment's benefit for you.
TB-500 human healing time is still unknown
In rat wounds, thymosin beta-4 increased new skin growth by about 42% at 4 days and up to 61% more at 7 days [3]. Researchers used skin treatment or shots inside the belly. Those days describe rats given a different substance. Your wound's healing time can't be calculated from that rat response.
TB-500 timing claims lack a reliable human test
TB-500 half-life means the time taken for your body to remove half the amount present. Human studies haven't established that time. An early Phase 1 study found that larger amounts of whole thymosin beta-4 remained longer [6]. Sports tests look for the fragment, but don't establish how long treatment lasts for you.
Pharmacy access doesn't decide permission in sport
Law 503A covers medicine made for your prescription. WADA sets sports bans. Pharmacy permission doesn't grant permission in sport.
TB-500's earlier risk listing didn't grant approval
TB-500 has no FDA-approved human treatment use. FDA earlier placed the thymosin beta-4 fragment called TB-500 in 503A Category 2 for possible safety risks. Those risks included immune system reactions and missing safety information. The later withdrawal of the ingredient request didn't grant drug approval for you.
WADA testing can find the banned TB-500 fragment
WADA prohibits TB-500 in the sports covered by its rules. Both contest use and use away from contests are barred. Tests detect the fragment in human or horse blood and urine. Your sports ban remains in force whatever happens to pharmacy status.
TB-500's withdrawn request hasn't settled pharmacy use
FDA hasn't approved TB-500 as a drug, though suppliers offer the substance for lab research. In some countries, a prescription is needed for the substance. The person or group seeking ingredient permission withdrew the request, and FDA stopped listing the fragment in Category 2 without explaining pharmacy permission. You can read the legal-status page about the named-patient law, 503A, and the separate WADA sports ban.
TB-500 pharmacy review remains separate from permission
FDA's page current as of April 22, 2026 records the withdrawn TB-500 request and no Category 2 listing. Your pharmacy still lacks FDA's explanation of permission to use the fragment. Pharmacy advisers discussed the fragment in July 2026, while staff urged against ingredient listing. Without a published account of votes, the meeting can't give your pharmacy a final answer.
FDA's earlier pharmacy risk listing didn't approve TB-500
FDA's September 29, 2023 update put the thymosin beta-4 fragment called TB-500 in 503A Category 2 for possible serious risks. Under pharmacy law 503A, some ingredients can be made into medicine during FDA review; Category 2 ingredients weren't allowed that way. The party seeking ingredient permission later withdrew the request. FDA's page current as of April 22, 2026 no longer shows TB-500 in that category, which doesn't establish approval for you.